Hyphens Pharma International Limited announce that it has signed an exclusive distribution agreement with Cooper Pharma, S.A. for the Group's Ceradan® range of products to be distributed in five Middle East countries, namely Saudi Arabia, United Arab Emirates, Kuwait, Qatar and Bahrain. Cooper Pharma will be responsible for the product registration and commercialisation of Ceradan® products in the five countries. Ceradan® is Hyphens Pharma's brand of dermatological products and it has a unique ceramide-dominant emollient formulation.

Ceradan® products, which are scientifically-formulated and clinically-tested to relieve and tackle eczema-prone skin conditions, are poised to benefit from the growing eczema market in the Middle East.